Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study - Université Clermont Auvergne Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2020

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

Marie Selvy
  • Fonction : Auteur
  • PersonId : 1081263
Bruno Pereira
Nicolas Kerckhove
Coralie Gonneau
  • Fonction : Auteur
  • PersonId : 1081266
Gabrielle Feydel
  • Fonction : Auteur
  • PersonId : 1081267
Caroline Pétorin
  • Fonction : Auteur
  • PersonId : 1081268
Agnès Vimal-Baguet
  • Fonction : Auteur
  • PersonId : 1081269
Sergey Melnikov
  • Fonction : Auteur
  • PersonId : 1081270
Sharif Kullab
  • Fonction : Auteur
  • PersonId : 1081271
Vincent Bourgeois
  • Fonction : Auteur
David Tavan
  • Fonction : Auteur
Kheir Eddine Benmammar
  • Fonction : Auteur
Brigitte Monange
  • Fonction : Auteur
Mohamed Ramdani
Floriane Huet-Penz
  • Fonction : Auteur
Ahmed Bedjaoui
  • Fonction : Auteur
Florent Genty
  • Fonction : Auteur
Jérôme Busserolles
  • Fonction : Auteur
  • PersonId : 1081273
David Balayssac

Résumé

(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8-36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients.
Fichier principal
Vignette du fichier
jcm-09-02400-v2.pdf (1.56 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-02997588 , version 1 (25-05-2021)

Licence

Paternité

Identifiants

Citer

Marie Selvy, Bruno Pereira, Nicolas Kerckhove, Coralie Gonneau, Gabrielle Feydel, et al.. Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. Journal of Clinical Medicine, 2020, 9 (8), pp.2400. ⟨10.3390/jcm9082400⟩. ⟨hal-02997588⟩
122 Consultations
180 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More